Idogen strengthens its position in the USA – important patent application receives Notice of Allowance
Idogen AB (”Idogen”) today announces that the United States Patent & Trademark Office (”USPTO”) has issued a “Notice of Allowance”, which means that it intends to grant Idogen’s patent application. In January 2017, the company was granted a patent for its tolerogenic vaccine technology in Japan and a related application was approved for grant in Europe. The US patent will provide Idogen’s tolerogenic vaccine technology with broad protection in a key market and significantly strengthens the company’s patent portfolio.
The United States Patent & Trademark Office (USPTO) has communicated its intention to grant Idogen’s Patent Application No. 14/553,098 . The patent belongs to Idogen’s second patent family and covers Idogen’s technology for induction of IDO for treatment of autoimmune diseases and transplant rejection. Once the issue fee is paid by Idogen and necessary formalities have been completed by the USPTO, the patent will be granted. The patent term will then extend to December 2031, potentially longer if adjustment is made for any delays in the processing at the patent office.
Related applications were granted in Japan and the subject of a “Notice of Intention to Grant” in Europe in January 2017. A further related application is pending in Canada. The granted patent will complement the Japanese granted patent in this family and an earlier European Patent in Idogen’s first patent family, granted in December 2013.
CEO Lars Hedbys commented that ” This patent provides very important protection for our tolerogenic vaccine platform in the USA. This is a key market representing 40% of the global pharmaceutical market and is important territory for innovative therapies such as ours. The decision that the USPTO will grant a patent gives us great encouragement ” .
For additional information about Idogen, please contact:
Lars Hedbys, CEO
Tel: +46 (0)46-275 63 30
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 13th of March 2017.
Idogen develops tolerogenic vaccines which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement.
The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company's technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com